Homocysteine and serum markers of immune activation in primary dystonia
Identifieur interne : 003896 ( Main/Exploration ); précédent : 003895; suivant : 003897Homocysteine and serum markers of immune activation in primary dystonia
Auteurs : Ulf J. Muller [Autriche] ; Barbara Frick [Autriche] ; Christiana Winkler [Autriche] ; Dietmar Fuchs [Autriche] ; Gregor K. Wenning [Autriche] ; Werner Poewe [Autriche] ; Joerg Mueller [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Anti-Dyskinesia Agents (therapeutic use), Biological Markers (blood), Botulinum Toxins (therapeutic use), C-Reactive Protein (metabolism), Chromatography, High Pressure Liquid (methods), Dystonia, Dystonic Disorders (blood), Dystonic Disorders (classification), Dystonic Disorders (drug therapy), Dystonic Disorders (immunology), Female, Folic Acid (blood), Follow-Up Studies, Homocystein, Homocysteine (blood), Humans, Immunity (drug effects), Immunity (physiology), Male, Middle Aged, Neopterin, Nervous system diseases, Vitamin B 12 (blood), dystonia, homocysteine, immune activation, neopterin.
- MESH :
- chemical , blood : Biological Markers, Folic Acid, Homocysteine, Vitamin B 12.
- chemical , metabolism : C-Reactive Protein.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- blood : Dystonic Disorders.
- classification : Dystonic Disorders.
- drug effects : Immunity.
- drug therapy : Dystonic Disorders.
- immunology : Dystonic Disorders.
- methods : Chromatography, High Pressure Liquid.
- physiology : Immunity.
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged.
Abstract
The cause of primary dystonia remains unknown. Several reports point to immune system disturbances in primary dystonia and a recent study demonstrated hyperhomocysteinemia in cervical dystonia. Homocysteine (HCY) is an amino acid and elevated HCY concentrations were shown to be associated with immune system activation and increased neopterin serum concentrations. We examined HCY serum concentrations together with serum markers of immune activation in patients with different types of primary dystonia. Eighty‐three patients with different types of primary dystonia were included and investigated at least 3 months following botulinum toxin treatment. Thirty‐six healthy volunteers with similar age and sex distribution served as controls. Total serum HCY, kynurenine, and tryptophan concentrations were determined by high‐performance liquid chromatography; neopterin, folate, and vitamin B12 concentrations were measured by immunoassays. Routine blood analysis, including C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood count (WBC), was performed. Patients with primary dystonia had significantly higher HCY concentrations compared to controls. Among the dystonia subtypes, no significant difference of HCY serum concentrations was observed. CRP and ESR were within the normal range in >90% of the patients and all had normal WBC. Neopterin, kynurenine, and tryptophan serum concentrations were similar in patients and controls and not correlated with HCY serum concentrations. The results provide evidence against enhanced cellular immune activation in patients with primary dystonia. However, hyperhomocysteinemia was present in all dystonia subtypes and unrelated to immune activation in this study. HCY is a neuronal excitotoxic amino acid and hyperhomocysteinemia is considered an independent vascular risk factor. Further studies are required to define the background of hyperhomocysteinemia in primary dystonia. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20667
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001110
- to stream Istex, to step Curation: 001110
- to stream Istex, to step Checkpoint: 002304
- to stream PubMed, to step Corpus: 002F15
- to stream PubMed, to step Curation: 002F15
- to stream PubMed, to step Checkpoint: 003107
- to stream Ncbi, to step Merge: 001397
- to stream Ncbi, to step Curation: 001397
- to stream Ncbi, to step Checkpoint: 001397
- to stream Main, to step Merge: 004F81
- to stream PascalFrancis, to step Corpus: 001C14
- to stream PascalFrancis, to step Curation: 001107
- to stream PascalFrancis, to step Checkpoint: 001E30
- to stream Main, to step Merge: 005308
- to stream Main, to step Curation: 003896
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Homocysteine and serum markers of immune activation in primary dystonia</title>
<author><name sortKey="Muller, Ulf J" sort="Muller, Ulf J" uniqKey="Muller U" first="Ulf J." last="Muller">Ulf J. Muller</name>
</author>
<author><name sortKey="Frick, Barbara" sort="Frick, Barbara" uniqKey="Frick B" first="Barbara" last="Frick">Barbara Frick</name>
</author>
<author><name sortKey="Winkler, Christiana" sort="Winkler, Christiana" uniqKey="Winkler C" first="Christiana" last="Winkler">Christiana Winkler</name>
</author>
<author><name sortKey="Fuchs, Dietmar" sort="Fuchs, Dietmar" uniqKey="Fuchs D" first="Dietmar" last="Fuchs">Dietmar Fuchs</name>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Mueller, Joerg" sort="Mueller, Joerg" uniqKey="Mueller J" first="Joerg" last="Mueller">Joerg Mueller</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:154ACE0E7C6D7E89E0A8BAE30E1C15DB19278962</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20667</idno>
<idno type="url">https://api.istex.fr/document/154ACE0E7C6D7E89E0A8BAE30E1C15DB19278962/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001110</idno>
<idno type="wicri:Area/Istex/Curation">001110</idno>
<idno type="wicri:Area/Istex/Checkpoint">002304</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Muller U:homocysteine:and:serum</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16108020</idno>
<idno type="wicri:Area/PubMed/Corpus">002F15</idno>
<idno type="wicri:Area/PubMed/Curation">002F15</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003107</idno>
<idno type="wicri:Area/Ncbi/Merge">001397</idno>
<idno type="wicri:Area/Ncbi/Curation">001397</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001397</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Muller U:homocysteine:and:serum</idno>
<idno type="wicri:Area/Main/Merge">004F81</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0191545</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C14</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001107</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E30</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Muller U:homocysteine:and:serum</idno>
<idno type="wicri:Area/Main/Merge">005308</idno>
<idno type="wicri:Area/Main/Curation">003896</idno>
<idno type="wicri:Area/Main/Exploration">003896</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Homocysteine and serum markers of immune activation in primary dystonia</title>
<author><name sortKey="Muller, Ulf J" sort="Muller, Ulf J" uniqKey="Muller U" first="Ulf J." last="Muller">Ulf J. Muller</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>University Hospital of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frick, Barbara" sort="Frick, Barbara" uniqKey="Frick B" first="Barbara" last="Frick">Barbara Frick</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Institute for Medical Chemistry and Biochemistry, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Winkler, Christiana" sort="Winkler, Christiana" uniqKey="Winkler C" first="Christiana" last="Winkler">Christiana Winkler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Institute for Medical Chemistry and Biochemistry, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fuchs, Dietmar" sort="Fuchs, Dietmar" uniqKey="Fuchs D" first="Dietmar" last="Fuchs">Dietmar Fuchs</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Institute for Medical Chemistry and Biochemistry, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>University Hospital of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>University Hospital of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Mueller, Joerg" sort="Mueller, Joerg" uniqKey="Mueller J" first="Joerg" last="Mueller">Joerg Mueller</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>University Hospital of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-12">2005-12</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1663">1663</biblScope>
<biblScope unit="page" to="1667">1667</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">154ACE0E7C6D7E89E0A8BAE30E1C15DB19278962</idno>
<idno type="DOI">10.1002/mds.20667</idno>
<idno type="ArticleID">MDS20667</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Biological Markers (blood)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>C-Reactive Protein (metabolism)</term>
<term>Chromatography, High Pressure Liquid (methods)</term>
<term>Dystonia</term>
<term>Dystonic Disorders (blood)</term>
<term>Dystonic Disorders (classification)</term>
<term>Dystonic Disorders (drug therapy)</term>
<term>Dystonic Disorders (immunology)</term>
<term>Female</term>
<term>Folic Acid (blood)</term>
<term>Follow-Up Studies</term>
<term>Homocystein</term>
<term>Homocysteine (blood)</term>
<term>Humans</term>
<term>Immunity (drug effects)</term>
<term>Immunity (physiology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neopterin</term>
<term>Nervous system diseases</term>
<term>Vitamin B 12 (blood)</term>
<term>dystonia</term>
<term>homocysteine</term>
<term>immune activation</term>
<term>neopterin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biological Markers</term>
<term>Folic Acid</term>
<term>Homocysteine</term>
<term>Vitamin B 12</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Dystonic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Dystonic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Immunity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Dystonic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chromatography, High Pressure Liquid</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Immunity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Homocystéine</term>
<term>Néoptérine</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The cause of primary dystonia remains unknown. Several reports point to immune system disturbances in primary dystonia and a recent study demonstrated hyperhomocysteinemia in cervical dystonia. Homocysteine (HCY) is an amino acid and elevated HCY concentrations were shown to be associated with immune system activation and increased neopterin serum concentrations. We examined HCY serum concentrations together with serum markers of immune activation in patients with different types of primary dystonia. Eighty‐three patients with different types of primary dystonia were included and investigated at least 3 months following botulinum toxin treatment. Thirty‐six healthy volunteers with similar age and sex distribution served as controls. Total serum HCY, kynurenine, and tryptophan concentrations were determined by high‐performance liquid chromatography; neopterin, folate, and vitamin B12 concentrations were measured by immunoassays. Routine blood analysis, including C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood count (WBC), was performed. Patients with primary dystonia had significantly higher HCY concentrations compared to controls. Among the dystonia subtypes, no significant difference of HCY serum concentrations was observed. CRP and ESR were within the normal range in >90% of the patients and all had normal WBC. Neopterin, kynurenine, and tryptophan serum concentrations were similar in patients and controls and not correlated with HCY serum concentrations. The results provide evidence against enhanced cellular immune activation in patients with primary dystonia. However, hyperhomocysteinemia was present in all dystonia subtypes and unrelated to immune activation in this study. HCY is a neuronal excitotoxic amino acid and hyperhomocysteinemia is considered an independent vascular risk factor. Further studies are required to define the background of hyperhomocysteinemia in primary dystonia. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Muller, Ulf J" sort="Muller, Ulf J" uniqKey="Muller U" first="Ulf J." last="Muller">Ulf J. Muller</name>
</noRegion>
<name sortKey="Frick, Barbara" sort="Frick, Barbara" uniqKey="Frick B" first="Barbara" last="Frick">Barbara Frick</name>
<name sortKey="Fuchs, Dietmar" sort="Fuchs, Dietmar" uniqKey="Fuchs D" first="Dietmar" last="Fuchs">Dietmar Fuchs</name>
<name sortKey="Mueller, Joerg" sort="Mueller, Joerg" uniqKey="Mueller J" first="Joerg" last="Mueller">Joerg Mueller</name>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<name sortKey="Winkler, Christiana" sort="Winkler, Christiana" uniqKey="Winkler C" first="Christiana" last="Winkler">Christiana Winkler</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003896 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003896 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:154ACE0E7C6D7E89E0A8BAE30E1C15DB19278962 |texte= Homocysteine and serum markers of immune activation in primary dystonia }}
This area was generated with Dilib version V0.6.23. |